Skip to content

Amanta Healthcare Limited (AMANTA)

Small Cap

Pharma stocks · Small cap · NSE

Amanta Healthcare Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.

₹160.18
-4.45 · -2.70%
Market cap ₹739 Cr
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm IST
Details
Quote21 Oct, 03:31 pm IST
Base fundamentals03 Oct 2026 · screener
Latest result06 Aug, 12:02 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens

Trend score and candlestick chart

66Bullish

SMA20 -3.7% / mo · MACD − · sector +4.9pp vs Nifty 500 (3M)

Stock trend: 43
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%

FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence

Technical chart

AMANTAD candles · FIT view+19.0%
Latest close ₹160.18 on 2026-10-21
Bar
-4.7%
RSI
34
MACD hist
-3.45
52W pos
58%
Visible chart range
Candle interval
2026-10-21O ₹168.00H ₹169.67L ₹151.71C ₹160.18Vol 3.2L sh
₹107.73₹134.50₹161.27₹188.05₹214.8252H₹160.182026-032026-06VolRSIMACD2026-042026-062026-082026-092026-11
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context

Relative performance and chart statistics

Adjusted completed-session prices, rebased to 100

AMANTANifty PharmaNifty 500
-12%+1%+14%+27%21 Jul2 Sept21 Oct21 Oct 2026AMANTA -4.6%Nifty Pharma -2.0%Nifty 500 -6.5%
AMANTA
-4.6%
Nifty 500
-6.5%
Nifty Pharma
-2.0%
Vs Nifty 500
+1.9 pp
Chart stats
21 Oct 2026
From 52W high
-23.7%
₹210
52W range position
58%
₹92 - ₹210
ATR (14)
6.0%
₹9.6
Volume vs 20D
5.64x
Latest completed session
Avg traded value
₹1.3 Cr
20-session average
20D price channel
₹151.7 - ₹207.6
61.5% annualized volatility
Research snapshot

What the evidence says now

Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.

Weak U-Score but strong trend: momentum may be ahead of fundamentals.

Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · WATCHLIST
39

Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.

Latest result
Bad
0

Revenue +5.3% · PAT -5.7% YoY

Technical
Bullish
66

Price trend and sector-relative-strength timing.

Valuation
Legacy model
+5.6%

Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.

Trust
Limited evidence
61

Financial-only signal; management claim evidence is not sufficient yet.

Financials

Fundamentals, quarterly history, margins, returns and balance-sheet evidence

Latest result

Quarter ended 30 Jun 2026

Bad · 0/100

PAT -6% YoY · margin compression · Rev +5% YoY

Filed 05 Aug 2026
Open results browser →
MetricThis quarterYoYQoQ
Revenue₹68.8 Cr+5.3%-10.6%
EBITDA₹14.5 Cr-2.4%-2.8%
Operating margin21.1%-168 bps+170 bps
PAT₹3.3 Cr-5.7%-40.1%
PAT margin4.8%-56 bps-237 bps

NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.

Fundamentals

Valuation

P/E
48.20
P/B
3.35
EV/EBITDA
12.44
Market Cap
739.00Cr

Profitability

ROE
10.30%
ROCE
11.60%
ROA
2.69%
Dividend Y
—

Growth (CAGR)

Revenue 5Y
11.00%
EPS 5Y
22.00%
Revenue 3Y
4.00%
EPS 3Y
55.00%

Balance Sheet

Debt/Equity
1.11
Interest Coverage
3.00×
Altman Z
2.78
Book Value
56.70

Cash Flow

FCF Yield
—
FCF Positive Y
6/5
OCF
48.00 Cr
EPS TTM
3.77

Shareholding

Promoter Hold
63.79%
Promoter Pledge
0.00%
Momentum 52W
83%

Financial History

Updated 20/10/2026

Revenue

₹ Cr
Latest: 288+4.7% vs prev
0288.0Mar 2020: 184Mar 2021: 171Mar 2022: 225Mar 2023: 259Mar 2024: 280Mar 2025: 275Mar 2026: 288FY20FY21FY22FY23FY24FY25FY26

Net Profit

₹ Cr
Latest: 15.0+50.0% vs prev
-22.0055.0Mar 2020: -19.0Mar 2021: -22.0Mar 2022: 55.0Mar 2023: -2.0Mar 2024: 4.0Mar 2025: 10.0Mar 2026: 15.0FY20FY21FY22FY23FY24FY25FY26

Return on Equity

%
Latest: 6.8-33.9% vs prev
-314.3087.3Mar 2020: -65.5%Mar 2021: -314%Mar 2022: 87.3%Mar 2023: -3.2%Mar 2024: 6.1%Mar 2025: 10.3%Mar 2026: 6.8%FY20FY21FY22FY23FY24FY25FY26

Technicals

Trend interpretation, Stage 2, relative strength, volume and indicator evidence

Daily technical trend read

Bearish setup

Trend is weak — long-term uptrend intact. RSI 34.

  • Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
  • SMA20 falling (~3.8% over last month) — short-term momentum negative.
  • RSI(14) at 34 — falling, no extreme reading.
  • MACD below signal, histogram expanding negatively — bearish momentum building.
  • 24% off 52W high · 74% above 52W low.

Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.

Nifty 500 leadership

Relative Strength & Trend Stage

82
RS percentile
Stage 2 UptrendEstablished S2
1M return
-14.8%
3M return
-4.6%
6M return
+17.0%
1Y return
+30.8%
RS 1D
+1
RS 20D
-5
Sector rank
#1
Industry rank
#9
Stage evidence
  • Price is 2.8% above the 30-week proxy.
  • The 50-DMA is above the 30-week proxy and its slope is rising +8.1%.
50-DMA
price below
200-DMA
price above
S2 entered
28 May 2026
S2 age
102 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 119.1-1.80%
6487110134157Sept 25Feb 26Jun 26Oct 26119
RS vs Nifty 500119

Valuation & peers

U-Score 39 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies

39U-SCORE
WATCHLIST

Fundamental score breakdown

U band · WATCHLIST
Valuation4/30
Growth19/25
Quality2/20
Balance Sheet5/15
Cash Flow4/10
Piotroski
7/9 (+5)
Penalties
0
Raw sum
39

Why this score?

Top U-Score contributors and drags from the latest stored fundamentals.

39/100 · legacy band WATCHLIST

Positive drivers

  • Piotroski is strong at 7/9.
  • Growth contributes 19/25 to the score.
  • Cash flow contributes 4/10 to the score.

Main drags

  • Quality is weaker at 2/20; verify the latest quarterly trend.
  • Valuation is weaker at 4/30; verify the latest quarterly trend.
  • Balance sheet is weaker at 5/15; verify the latest quarterly trend.
Sector valuation model

Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks

Healthcare valuation needs both earnings quality and regulatory/pipeline context.

Pharma PE/EVEBITDA
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
48.2
PB
3.4
EV/EBITDA
12.4
ROE
10.3%
ROCE
11.6%
FCF Yield
—
Debt/Equity
1.1
MoS
+5.6%
Score movement

Stored run vs live recompute

This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.

Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
39
Previous: 39
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
+5.6%
Previous: +3.0%

Score history

12 stored score snapshots. Latest stored move: +0 points.

21 Oct 2026
v4.3-runtime-valuation
37
37
37
37
37
37
37
37
37
37
39
39

Factor attribution

No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.

Modelled fair value

Graham Number
₹69.35
-131.0% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹169.65
+5.6% MoS
PEG
1.37

Comparable companies

Peers

Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.

Compare all ↗
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
ANUHPHR
Small
Anuh Pharma Limited
Pharmaceuticals
match 166
40
19.5
10.7%
+40%
WATCHLIST
BAFNAPH
Small
Bafna Pharmaceuticals Limited
Pharmaceuticals
match 165
27
—
-6.2%
—
OVERVALUED
WANBURY
Small
Wanbury Limited
Pharmaceuticals
match 165
69
11.2
68.4%
+74%
UNDERVALUED
ALBERTDAVD
Small
Albert David Limited
Pharmaceuticals
match 164
26
21.7
-0.4%
-23%
OVERVALUED
HALEOSLABS
Small
HALEOS LABS LIMITED
Pharmaceuticals
match 163
29
29.6
8.4%
-139%
OVERVALUED

Business, management & trust

Growth engines, risks, management commitments and evidence-backed delivery

Business and thesis

Issuer presentation review pending

Amanta Healthcare Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.

Trust Score
61Limited evidence · low confidenceTrust Lite

Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.

Limited evidence: Claim history is still being built. It ranks around the 32nd percentile of the scored universe and 22nd percentile within Pharma. Main check: results consistency is weak at 46/100.

This is a financial-behaviour screen, not a claim-tested management reliability verdict.

Computed 05 Sept 2026
management-trust-v1
14 docs text-extracted · 4 concalls text-extracted
Score band
Limited evidence

Financial behaviour is scored, but management claims do not yet have enough outcome checks.

Relative rank
32nd percentile

overall median 67 · Pharma: 22nd pctile, median 70 · Small: 36th pctile, median 66

Evidence depth
Financial-only

14 documents have extracted text, but claim history is not strong enough yet.

Claim delivery
Outcome history still building

0 claims extracted · No contradicted claim yet

How to read this Trust Score

Limited evidence · low confidence
What it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.

Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.

Forensic breakdown

Read low sub-scores as due-diligence warnings, not automatic sell signals.

Promoter
86
strong · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
53
watch · leverage and solvency
Discipline
50
watch · capital discipline
Results
46
watch · quarterly consistency

Trust positives

  • ▸Promoter holding is 63.8%.
  • ▸Promoter pledge is zero.
  • ▸6 years of positive FCF.
  • ▸4/4 latest quarters had positive YoY revenue growth.

Trust risks

  • ▸Debt/equity is 1.11.
  • ▸ROCE trend is -2.1%.
  • ▸1/4 latest quarters had positive YoY PAT growth.
  • ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.

Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.

Important announcements & filings

Latest exchange and company disclosures found within the past two years.

12 shown
AnnouncementSep 2026

Sep 2026 · Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Amanta Healthcare Limited Announces Commissioning Of New Steriport Line 2 Sep - Amanta Healthcare commissioned new SteriPort line at Kheda on September 2, 2026, boosting production and margins.

Source: Bse

Open source ↗
Annual reportSep 2026

Sep 2026 · Intimation - Regulation 36(1)(B) Of The SEBI Listing Regulations 25 Aug - 31st AGM on 16 September 2026; annual report web-link shared and KYC reminder issued.

Source: Bse

Open source ↗
Annual reportSep 2026

Sep 2026 · Annual Report For Financial Year 2025-26 24 Aug - Annual Report 2025-26 and 31st AGM notice; meeting on September 16, 2026 via VC/OAVM.

Source: Bse

Open source ↗
Announcement

Announcement under Regulation 30 (LODR)-Change in Management 16 Sep - AGM approved Nimesh Patel as director and Kashyap R. Mehta & Partners as secretarial auditor for 2026-31.

Source: Bse

Open source ↗
Announcement

Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015 3 Sep - Newspaper advertisement issued for special window on transfer and dematerialisation of physical shares.

Source: Bse

Open source ↗
Investor presentationAug 2026

Aug 2026 · PPT

Source: Bse

Open source ↗
Concall transcriptAug 2026

Aug 2026 · Transcript

Source: Bse

Open source ↗
Annual report

Announcement under Regulation 30 (LODR)-Newspaper Publication 25 Aug - Newspaper Advertisement for dispatch of Annual Report of the 31st Annual General Meeting and e-voting information

Source: Bse

Open source ↗
Announcement

Announcement under Regulation 30 (LODR)-Newspaper Publication 12 Aug - Submission of Newspaper clippings - Advertisement addressed to the Shareholders for Annual General Meeting

Source: Bse

Open source ↗
Announcement

Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Aug

Source: Bse

Open source ↗
AnnouncementJul 2026

Jul 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 9 Jul - Amanta Healthcare held virtual investor meeting with ValPro Capital on July 9, 2026.

Source: Bse

Open source ↗
Announcement

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 6 Jul

Source: Bse

Open source ↗
Verify on:NSE India ↗
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.